摘要
目的:探讨孟鲁司特联合特布他林和布地奈德治疗哮喘急性发作的效果。方法:选取某院2015年1月~2016年12月收治的60例支气管哮喘急性急性发作患者,将其随机分为实验组与对照组每组30例,在对症支持治疗的基础上,对照组患者接受布地奈德雾化吸入+硫酸特布他林口服治疗,实验组在此基础上,接受孟鲁司特钠咀嚼片治疗,比较两组患者的临床疗效和肺功能。结果:实验组和对照组的总有效率分别是93.33%和73.33%(P<0.05);治疗后两组患者FEV1、FVC以及PEF较本组治疗前均有明显的升高(P<0.05),其中实验组患者较对照组升高更加明显(P<0.05);组间不良反应发生情况无显著差异(P>0.05)。讨论:孟鲁司特、特布他林和布地奈德3种药物联合使用治疗哮喘急性发作具有明显的临床疗效,可显著改善患者的肺功能,适合推广。
Objective： To investigate the efficacy of Montelukast Combined with terbutaline and budesonide in the treatment of acute attack of asthma. Methods： 60 cases of acute bronchial asthma acute attack patients in a hospital from January 2015 - 2016 year in December were randomly divided into experimental group and control group with 30 cases in each group. On the basic of effective treatment, the control group received budesonide inhalation terbutaline sulfate ＋Linkou clothing treatment and the experimental group accepted another Montelukast Sodium Chewable Tablets treatment. Then we compared two groups of patients with clinical efficacy and lung function. Results： The results of the experimental group and the control group in the total efficiency were 93.33% and 73.33% （P〈0.05） ; the two groups after treatment with FEV1, FVC and PEF were significantly higher （P〈0.05） than before. And the increase for experimental was significantly obvious （P〈0.05） ; there was no significant difference （P〉0.05） in terms of the incidence of adverse reactions between two groups. Conclusion： The combined use of montelukast, terbutaline and budesonide in the treatment of acute attack of asthma has obvious clinical efficacy, and can significantly improve the lung func tion of patients, so it deserves promotion.
出处
《数理医药学杂志》
2017年第12期1833-1834,共2页
Journal of Mathematical Medicine
